Key Takeaways Novo Nordisk's U.S.-listed shares lost ground Friday after a Phase 2a trial of the pharmaceutical firm’s latest ...

Ozempic maker Novo Nordisk (NVO) announced mixed results today for a phase 2 trial of an experimental weight loss pill that ...

This post was written by Melanie Riehl Novo Nordisk (NVO) stock is falling Friday morning after ... Shares of FedEx (FDX) are plummeting in after-hours trading. The shipping giant reported first ...

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $70 ...

President Joe Biden’s Inflation Reduction Act allows Medicare to negotiate costly drug prices with pharmaceutical companies.

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...

J.P. Morgan analyst Richard Vosser maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of ...

Friday, shares of Novo Nordisk A/S (NVO) are sliding following the announcement of safety results of phase 2a clinical trial of ...

Novo Nordisk has multiple, strong upcoming, positive catalysts, related to its GLP-1 weight-loss drugs, Ozempic and Wegovy.

Out of all of the special options we uncovered, 7 are puts, for a total amount of $295,009, and 5 are calls, for a total ...

Eli Lilly surged 58% in 2024, driven by weight-loss drugs and strong earnings. The technical chart shows consolidation. See ...

Novo Nordisk said on Wednesday its highly anticipated experimental weight-loss pill amycretin was safe and tolerable for ...